ITEM STATUS:Authorised ITEM NUMBER:119735 LEGACY RELEASE DATE:03-Sep-15

TEXT SIZE CONTAINED IN THIS ARTWORK
Body text size: 8pt
Smallest text size: 6pt
Microtext: N

Note:
⇧ = Second version of new microprint mark

Page 1 of 2

Poznan – Additional Artwork Information Panel	
Leaflet / dimensions after folding	N/A
Carton dimensions	60 x 63 x112 mm
Foil / Laminates width	N/A
Label dimensions	N/A
Tube dimensions	N/A
Replacement No.:	119413
Point of sale code No.:	EAN 13: 7800029002008

GlaxoSmithKline Artwork Information Panel — RSC A/W Version: 1

Item Number: 119735

Manufacturing Site: GSK-POL-Poznan-PLPZN

Market or Pack Owner: Chile-CHL

Market Trade Name: Combivir

No. of Colours: 4
(does NOT include Varnish, if applicable)

List Colours:
(include sample in fields provided below; e.g. spot / spot-CMYK equivalent)

C	571	K	1505
			Varnish

Technical Reference No(s).: DRW_C_105N_06_STD
(do NOT include the technical reference doc[s] version no[s].)

Artwork copyright is the property of the GlaxoSmithKline Group of Companies
All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork.
The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers.
The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.

ATTENTION • ATTENTION

To Ensure Accurate PDF Viewing and Printing:
FOR SCREEN VIEWING: Use Adobe Acrobat 5 Professional or Adobe Acrobat Reader, Standard or Professional (higher than 5). **Overprint Preview** must be activated for accurate on screen viewing.
FOR PRINTING: Use only Acrobat Professional version 5 or higher. **"Apply Overprint Preview"** or **"Simulate Overprinting"** must be activated in the print settings for printing accurate hard copies.

AIP_VERT_NAD_A1 - APR_2010 Version 2

180 mm Measuring Bar

If a status identification banner DOES NOT appear on this document, THEN this document has NOT been printed from the Global Pack Management system.

IMPORTANT

GSK Market is responsible for this product, its design and content.
Ensure the artwork is thoroughly checked, all the text proof-read and approved.
RSC GSK is responsible for site technical requirements and pre-press suitability.
GSK Market is responsible to advise RSC in case changes required impact the followings:
Formulation, Tablet embossing, Storage conditions, Shelf Life

This PDF has been verified using PitStop 08 - **PDF is PDF/X-1a compliant**
(Illustrator files workflow)

EXTRACTED ON:22-Aug-17 FILE VERSION:1 EXTRACTED FROM:GPM

Pharma code Ref. No. 6327



Pharma code Ref. No. 6327

TEXT SIZE CONTAINED IN THIS ARTWORK
Body text size: 8pt
Smallest text size: 6pt
Microtext: N

Note:

⇧ = Second version of new microprint mark

Page 2 of 2

Poznan – Additional Artwork Information Panel	
Leaflet / dimensions after folding	N/A
Carton dimensions	60 x 63 x112 mm
Foil / Laminates width	N/A
Label dimensions	N/A
Tube dimensions	N/A
Replacement No.:	119413
Point of sale code No.:	EAN 13: 7800029002008

GlaxoSmithKline Artwork Information Panel — RSC A/W Version: 1

Item Number: 119735

Manufacturing Site: GSK-POL-Poznan-PLPZN

Market or Pack Owner: Chile-CHL

Market Trade Name: Combivir

No. of Colours: 4
(does NOT include Varnish, if applicable)

List Colours:
(include sample in fields provided below; e.g. spot / spot-CMYK equivalent)

C	571	K	1505
			Varnish

Technical Reference No(s).: DRW_C_105N_06_STD
(do NOT include the technical reference doc[s] version no[s].)

Artwork copyright is the property of the GlaxoSmithKline Group of Companies
All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork.
The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers.
The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.

ATTENTION • ATTENTION

To Ensure Accurate PDF Viewing and Printing:
FOR SCREEN VIEWING: Use Adobe Acrobat 5 Professional or Adobe Acrobat Reader, Standard or Professional (higher than 5). **Overprint Preview** must be activated for accurate on screen viewing.
FOR PRINTING: Use only Acrobat Professional version 5 or higher. **"Apply Overprint Preview"** or **"Simulate Overprinting"** must be activated in the print settings for printing accurate hard copies.

AIP_VERT_NAD_AI - APR_2010 Version 2

180 mm Measuring Bar

If a status identification banner DOES NOT appear on this document, THEN this document has NOT been printed from the Global Pack Management system.

IMPORTANT

GSK Market is responsible for this product, its design and content.
Ensure the artwork is thoroughly checked, all the text proof-read and approved.
RSC GSK is responsible for site technical requirements and pre-press suitability.
GSK Market is responsible to advise RSC in case changes required impact the followings:
Formulation, Tablet embossing, Storage conditions, Shelf Life

ITEM STATUS:Authorised ITEM NUMBER:119412 LEGACY RELEASE DATE:03-Sep-15

Pharma code Ref. No. 325

70–76

Serie: Serie: Serie: Serie: Serie:

Combivir®
150/300 mg
comprimidos recubiertos
vía oral
Reg. I.S.P. N° F-0758
GlaxoSmithKline

Combivir®
150/300 mg
comprimidos recubiertos
vía oral
Reg. I.S.P. N° F-0758
GlaxoSmithKline
119412

Vence: Vence: Vence: Vence: Vence:

Serie: Serie: Serie: Serie: Serie:

Combivir® 150/300 mg comprimidos recubiertos vía oral Reg. I.S.P. N° F-0758 GlaxoSmithKline

Combivir® 150/300 mg comprimidos recubiertos vía oral Reg. I.S.P. N° F-0758 GlaxoSmithKline 119412

Vence: Vence: Vence: Vence: Vence: